New Cash Adds To Cardiome’s Bargaining Chips
This article was originally published in The Pink Sheet Daily
Executive Summary
Acquisition-hungry big pharma eyes the firm's oral vernakalant, ready for Phase III.
You may also be interested in...
For Amgen’s Nplate, No News Is Good News
FDA tells biotech the agency will miss once-postponed July 23 user fee date.
Sanofi-Aventis Heart Drug Multaq Back To FDA In Third Quarter
Follow-up ATHENA data bolsters NDA called “not approvable” in 2006.
Cardiome Reports Positive Oral Vernakalant Data; Says Company Sale Is Possible
Canadian firm retains Merrill Lynch to advise on merger and acquisition strategies the same day it reports positive data.